Genitourinary Cancer News

Several researchers and global oncology leaders received ASCO’s Special Awards, the society’s highest honors.

Thirty-four physicians have received Fellow of the American Society of Clinical Oncology distinction.

Adjuvant pembrolizumab appeared associated with a significant and clinically meaningful improvement in DFS vs. placebo among patients with clear cell renal carcinoma, according to results of the KEYNOTE-564 trial.

Established in 1992 in response to the HIV epidemic, the FDA’s accelerated approval program offers a valuable opportunity to make potentially lifesaving therapeutics available to patients in a timely manner.

Incidence of cervical cancer declined as rates of other HPV-associated cancers increased significantly in the U.S. from 2001 to 2017, according to a population-based study of trends presented during the virtual ASCO Annual Meeting.

Jordan Anaokar, MD, has been appointed site director for radiology at Fox Chase Cancer Center.

The FDA granted priority review to pembrolizumab plus lenvatinib for treatment of advanced renal cell carcinoma and advanced endometrial carcinoma, according to the agents’ manufacturers.

The Oncologic Drugs Advisory Committee voted this week to maintain four of six indications for checkpoint inhibitors that have received FDA accelerated approval.

The FDA granted priority review to nivolumab for adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma, according to the agent’s manufacturer.

About 4% of patients with advanced renal cell carcinoma had asymptomatic brain metastases, according to results of a retrospective multi-institutional cohort study published in Journal of the National Comprehensive Cancer Network.